Erratum to 'Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma' [Eur J Cancer 108 (February 2019) 33-40]
1 Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
2 Gastrointestinal Oncology Department, European Georges Pompidou Hospital, Université René Descartes, Paris, France; Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, Besançon, France; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France.
3 Medical Oncology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
4 Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
5 Department of Oncology, Tampere University Hospital and University of Tampere, Tampere, Finland.
6 Oncology Department, Centre Hospitalier Universitaire, Bordeaux, Aquitaine, France.
7 Department of Medical Oncology, University Hospital 12 de Octubre, I + 12, Madrid, Spain.
8 Barts Cancer Institute, Queen Mary University of London, London, UK.
9 Department of Medical Oncology, University Hospital, Besançon, France.
10 Oncology Department, European Georges Pompidou Hospital, Université René Descartes, Paris, France.
11 Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
12 Department of Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.
13 Department of Oncology, Centre Hospitalier Départemental Les Oudairies, La Roche-sur-Yon, France.
14 Medical Oncology, Institut René Gauducheau, Saint Herblain, France.
15 Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: [email protected].